Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally.
Excellent balance sheet with high growth potential.
Share Price & News
How has Sedana Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 7D2's share price has been volatile over the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: 7D2 exceeded the German Medical Equipment industry which returned 38.7% over the past year.
Return vs Market: 7D2 exceeded the German Market which returned -2.6% over the past year.
Price Volatility Vs. Market
How volatile is Sedana Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Sedana Medical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 7D2 (€24.3) is trading below our estimate of fair value (€44.9)
Significantly Below Fair Value: 7D2 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 7D2 is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: 7D2 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 7D2's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 7D2 is overvalued based on its PB Ratio (10x) compared to the DE Medical Equipment industry average (5x).
How is Sedana Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 7D2 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: 7D2 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 7D2's is expected to become profitable in the next 3 years.
Revenue vs Market: 7D2's revenue (35.7% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: 7D2's revenue (35.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 7D2's Return on Equity is forecast to be low in 3 years time (2.6%).
How has Sedana Medical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 7D2 is currently unprofitable.
Growing Profit Margin: 7D2 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 7D2 is unprofitable, and losses have increased over the past 5 years at a rate of -66.7% per year.
Accelerating Growth: Unable to compare 7D2's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 7D2 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (8.2%).
Return on Equity
High ROE: 7D2 has a negative Return on Equity (-2.05%), as it is currently unprofitable.
How is Sedana Medical's financial position?
Financial Position Analysis
Short Term Liabilities: 7D2's short term assets (SEK474.4M) exceed its short term liabilities (SEK24.3M).
Long Term Liabilities: 7D2 has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 7D2 is debt free.
Reducing Debt: 7D2 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 7D2 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 7D2 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Sedana Medical's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 7D2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 7D2's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 7D2's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 7D2's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 7D2's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Christer Ahlberg (48yo)
Mr. Christer Ahlberg serves as a Chief Executive Officer of Sedana Medical AB (publ) since February 1, 2017. He serves as President of Sedana Medical AB (publ) since February 2017. Mr. Ahlberg has many yea ...
CEO Compensation Analysis
Compensation vs Market: Christer's total compensation ($USD216.49K) is below average for companies of similar size in the German market ($USD1.08M).
Compensation vs Earnings: Christer's compensation has increased whilst the company is unprofitable.
|President & CEO||3.25yrs||kr2.10m||1.47% SEK7.9m|
|Chief Financial Officer||3.25yrs||no data||0.19% SEK1.1m|
|Chief Medical Officer||2.33yrs||no data||0.21% SEK1.1m|
Experienced Management: 7D2's management team is considered experienced (3.3 years average tenure).
|Independent Director||15.33yrs||kr50.00k||6.73% SEK36.4m|
|Independent Director||15.33yrs||kr50.00k||0.17% SEK925.1k|
|Independent Chairman of the Board||6.33yrs||kr283.30k||1.83% SEK9.9m|
|Independent Director||9.33yrs||kr50.00k||no data|
|Independent Director||2yrs||kr100.00k||0.014% SEK76.1k|
|Director||no data||no data||no data|
Experienced Board: 7D2's board of directors are considered experienced (9.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 7D2 insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.9%.
Sedana Medical AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Sedana Medical AB (publ)
- Ticker: 7D2
- Exchange: DB
- Founded: 2005
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: kr5.707b
- Listing Market Cap: kr541.169m
- Shares outstanding: 22.74m
- Website: https://www.sedanamedical.com
Number of Employees
- Sedana Medical AB (publ)
- VendevAegen 87
- Stockholm County
- 182 32
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SEDANA||OM (OMX Nordic Exchange Stockholm)||Yes||Share Capital||SE||SEK||Jun 2017|
|7D2||DB (Deutsche Boerse AG)||Yes||Share Capital||DE||EUR||Jun 2017|
Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers AnaConDa and AnaConDa-S, which are disposable medical devices that enables the administration of volatile anesthetics; AnaConDa Syringe, a 50/60ml syringe; FlurAbsorb, a charcoal filter for removing halogenated hydrocarbon anesthetic gases, such as isoflurane or sevoflurane; FlurAbsorb-S, a filter containing activated carbon for the removal of waste anaesthetic gases; FlurAbsorb accessory kit comprising lines and connectors for connecting the filter to the ventilator and gas monitor; and FlurAbsorb and FlurAbsorb-S mount to hold the filter during scavenging of anesthetic gas. It also provides isoflurane/sevoflurane and Sevorane QuickFil filling adaptors; gas sampling lines to prevent anaesthetic volatile agents from leaching through the wall of the tube; and Nafion lines to reduce the accumulation of condensate in the anaesthetic gas measuring line and the water trap of the gas monitor. In addition, the company develops IsoConDa, a therapy for inhalation sedation in intensive care. Sedana Medical AB (publ) was founded in 2005 and is headquartered in Danderyd, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/27 05:47|
|End of Day Share Price||2020/05/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.